206 related articles for article (PubMed ID: 15854180)
1. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
van Zonneveld M; Flink HJ; Verhey E; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Hansen BE; Schalm SW; Janssen HL;
Aliment Pharmacol Ther; 2005 May; 21(9):1163-71. PubMed ID: 15854180
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
[TBL] [Abstract][Full Text] [Related]
3. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China.
Zhao H; Kurbanov F; Wan MB; Yin YK; Niu JQ; Hou JL; Wei L; Wang GQ; Tanaka Y; Mizokami M; Si CW
Clin Infect Dis; 2007 Feb; 44(4):541-8. PubMed ID: 17243057
[TBL] [Abstract][Full Text] [Related]
4. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
Halász T; Farkas A; Tolvaj G; Horváth G
Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.
Buster EH; Hansen BE; Buti M; Delwaide J; Niederau C; Michielsen PP; Flisiak R; Zondervan PE; Schalm SW; Janssen HL;
Hepatology; 2007 Aug; 46(2):388-94. PubMed ID: 17604363
[TBL] [Abstract][Full Text] [Related]
6. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B.
Eser Karlidag G; Karlidag T; Demirdag K; Keles E
Auris Nasus Larynx; 2011 Jun; 38(3):312-8. PubMed ID: 21216118
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
8. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B.
Ketikoglou I; Karatapanis S; Elefsiniotis I; Kafiri G; Moulakakis A
Eur J Dermatol; 2005; 15(2):107-9. PubMed ID: 15757824
[TBL] [Abstract][Full Text] [Related]
9. [A multicenter, randomized, open-label study of the safety and effectiveness of pegylated interferon alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients].
Zhao H; Si CW; Wei L; Wan MB; Ying YK; Hou JL; Niu JQ
Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):323-6. PubMed ID: 16732903
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
12. [Safety of pegylated interferon in patients with hepatitis C virus induced cirrhosis].
Gasztonyi B; Pár G; Pár A; Hunyady B
Orv Hetil; 2005 Nov; 146(48):2431-4. PubMed ID: 16408382
[TBL] [Abstract][Full Text] [Related]
13. Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis.
Maan R; van der Meer AJ; Hansen BE; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Janssen HL; de Knegt RJ; Veldt BJ
J Gastroenterol Hepatol; 2015 Jun; 30(6):1057-64. PubMed ID: 25682797
[TBL] [Abstract][Full Text] [Related]
14. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
15. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
16. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
[TBL] [Abstract][Full Text] [Related]
19. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.
Neri S; Pulvirenti D; Bertino G
Clin Drug Investig; 2006; 26(11):655-62. PubMed ID: 17163300
[TBL] [Abstract][Full Text] [Related]
20. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
